A test that is able to detect trace levels of circulating tumor cells could help spot the early signs of treatment not working for advanced prostate cancer patients.
Checkpoint inhibitors increase median survival to 12.4 months, and more than double percentage of patients who survive 4 years or longer.
A Phase 1b clinical trial investigating tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer has yielded encouraging results.
This database study demonstrates variations in the utilization of hematopoietic cell transplantation in adult patients with acute lymphoblastic leukemia based on several biological and non-biological factors.
Find out more about the utility of clinical characteristics in the selection of patients with advanced NSCLC as potential candidates for single-agent anti-PD-1/PD-L1 immunotherapy in this open access Future Oncology review article.
Find out about the healthcare utilization and costs associated with diffuse large B-cell & follicular lymphoma patients treated in the US in this research article from Future Oncology.